Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome

Author Identifier

Mel Ziman

https://orcid.org/0000-0001-7527-3538

Document Type

Journal Article

Publication Title

Molecular Carcinogenesis

ISSN

1098-2744

Volume

58

Issue

9

First Page

1670

Last Page

1679

PubMed ID

31099111

Publisher

Wiley

School

School of Medical and Health Sciences

RAS ID

29154

Funders

Cancer Council Western Australia; cancer and palliative care research and evaluation unit WAPCN; Cancer League of Colorado; National Health and Medical Research Council, Grant/Award Number: 1013349; U.S. Department of Veterans Affairs, Grant/Award Number: 5I01BX001228; Interleukin Foundation for Medical Research Foundation for the National Institutes of Health, Grant/Award Numbers: R01CA197919, 1R03CA125833.

Grant Number

NHMRC Number : 1013349

Comments

Osborne, D. G., Domenico, J., Luo, Y., Reid, A. L., Amato, C., Zhai, Z., ... Fujita, M. (2019). Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Molecular Carcinogenesis, 58(9), 1670-1679. Available here

Abstract

Immune suppression is one of the 10 hallmarks of cancer. Interleukin‐37 (IL‐37), a member of the IL‐1 family, inhibits both innate and adaptive immunity, and has been shown to modulate immune responses in various disease conditions. Yet, IL‐37 has rarely been investigated in cancer patients, and its biological role in cancer remains to be elucidated. In this study, we investigated the gene expression of IL‐37 in age‐ and sex‐matched blood samples of healthy individuals and melanoma patients, and demonstrated upregulation of IL‐37 messenger RNA (mRNA) in the blood samples of melanoma patients. By further analyzing immune cell subsets responsible for the upregulated IL‐37 expression, we discovered that IL‐37 mRNA was highly expressed in T cells and granulocytes, with the highest expression in regulatory T (Treg) cells in healthy individuals, and that IL‐37 mRNA was upregulated in lymphocytes (T, B, and natural killer cells) in melanoma patient blood. Among all cell subsets, Treg cells from melanoma patients exhibited the highest IL‐37 gene expression levels. We provided evidence that melanoma‐conditioned media induces IL‐37 mRNA and protein expression in multiple lymphocyte populations, particularly in Treg cells. We further confirmed that the IL‐1‐mediated secretome from human melanoma cells, specifically transforming growth factor‐β, induces IL‐37 mRNA expression in human Treg cells. Our results suggest a potential immunosuppressive role for IL‐1 and IL‐37 in melanoma tumorigenesis. Highly elevated IL‐37 in specific lymphocyte populations could serve as a biomarker for tumor‐induced immunosuppression.

DOI

10.1002/mc.23044

Access Rights

free_to_read

Link to Full Text

Share

 
COinS